structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
07 févr. 2023 16h00 HE | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
structure_inline_fullcolor_rgb_12in@300ppi.png
硕迪生物宣布经增发的首次公开募股的定价
02 févr. 2023 20h59 HE | Structure Therapeutics Inc.
加利福尼亚州旧金山和中国上海, Feb. 03, 2023 (GLOBE NEWSWIRE) -- 硕迪生物技术有限公司(纳斯达克股票代码:GPCR)是一家临床阶段的全球化生物制药公司,致力于口服小分子药物的创新研发以治疗代谢性和肺部疾病。今日,公司宣布其经增发的首次公开募股的定价。公司拟发行10,740,000股美国存托股票(ADS),每股ADS代表三股普通股,公开发行价格为每股ADS...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
02 févr. 2023 19h41 HE | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
17 janv. 2023 01h00 HE | Kinarus Therapeutic Holding AG
 KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in...
Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target
10 janv. 2023 09h00 HE | InSilico Medicine
New York, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of...
logo.jpg
Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators
13 déc. 2022 16h05 HE | Vallon Pharmaceuticals Inc.
Combined company will operate as GRI Bio and advance innovative pipeline of Natural Killer T (NKT) regulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases GRI...
Algernon Logo 1.png
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
05 déc. 2022 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
16 nov. 2022 01h00 HE | Kinarus Therapeutic Holding AG
Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunitiesMultiple opportunities for KIN001 in indications with high unmet need are...
Algernon Logo 1.png
Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF
19 sept. 2022 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage...